| Bioactivity | Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). Tisotumab vedotin consists of a fully human monoclonal antibody to tissue factor (TF-011) conjugated to Monomethyl Auristatin E (MMAE). Tisotumab vedotin has good antitumor activity and can be used in the research of advanced or metastatic solid tumors[1]. |
| Name | Tisotumab vedotin |
| CAS | 1418731-10-8 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Markham A, et al. Tisotumab Vedotin: First Approval. Drugs. 2021 Dec;81(18):2141-2147. |